Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
    BMC Cancer. 2007 May 15;7:83.

    BRIP1 (BACH1) variants and familial breast cancer risk: a case-control study.

    Source

    Helmholtz-University Group Molecular Epidemiology, German Cancer Research Center, DKFZ, Heidelberg, Germany. b.frank@dkfz.de

    Abstract

    BACKGROUND:

    Inactivating and truncating mutations of the nuclear BRCA1-interacting protein 1 (BRIP1) have been shown to be the major cause of Fanconi anaemia and, due to subsequent alterations of BRCA1 function, predispose to breast cancer (BC).

    METHODS:

    We investigated the effect of BRIP1 -64G>A and Pro919Ser on familial BC risk by means of TaqMan allelic discrimination, analysing BRCA1/BRCA2 mutation-negative index patients of 571 German BC families and 712 control individuals.

    RESULTS:

    No significant differences in genotype frequencies between BC cases and controls for BRIP1 -64G>A and Pro919Ser were observed.

    CONCLUSION:

    We found no effect of the putatively functional BRIP1 variants -64G>A and Pro919Ser on the risk of familial BC.

    PMID:
    17504528
    [PubMed - indexed for MEDLINE]
    PMCID:
    PMC1887536
    Free PMC Article

      Supplemental Content

      Icon for BioMed Central Icon for PubMed Central

      Save items

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk